# Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

> **NCT03102320** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 173 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Anetumab ravtansine (BAY94-9343)

## Key facts

- **NCT ID:** NCT03102320
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-26
- **Primary completion:** 2020-09-16
- **Final completion:** 2021-07-26
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03102320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03102320, "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03102320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*